Discussing Evaporative Dry Eye: Incorporating New Treatments Into Practice (CME/CE Podcast)

Activity Description and Purpose

This podcast, with Kenneth A. Beckman, MD, FACS, and Jaclyn Garlich, OD, delves into the presentation and treatments of evaporative dry eye primarily caused by meibomian gland dysfunction (MGD). The discussion explores the multifactorial nature of dry eye disease (DED), emphasizing the significance of MGD-driven DED, which is characterized by a deficient tear lipid layer. The discussion also focuses on the latest treatment options, moving beyond traditional anti-inflammatory therapies to include newer topical solutions targeting evaporative loss. Real patient case studies contextualize these innovative approaches in the clinical management of DED. The desired results of this activity are to cement clinicians’ knowledge of the role of evaporation in the pathogenesis of MGD and help them obtain practical strategies for screening, diagnosis, and effective treatment that can improve patient outcomes.

Target Audience

This educational activity is intended for ophthalmologists and optometrists.

Learning Objectives

After completing this activity, participants will be better able to:

  • Incorporate diagnostic strategies that examine meibomian gland function in routine practice
  • Design evidence-based treatment plans for persons with meibomian gland dysfunction–associated dry eye disease
Course summary
Available credit: 
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 COPE
  • 0.50 Participation
Course opens: 
Course expires: 


Kenneth A. Beckman, MD, FACS
Clinical Assistant Professor of Ophthalmology
Ohio State University
Columbus, Ohio
Director of Corneal Surgery
Comprehensive Eye Care of Central Ohio
Westerville, Ohio

Jaclyn Garlich, OD
Envision Optometry
Glance by Eyes on Eyecare
Boston, Massachusetts

Disclosure Policy

MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.


Kenneth A. Beckman, MD, is a consultant for Alcon, Allergan, Avellino, Bausch & Lomb Incorporated, Bio-Tissue, Bruder Healthcare, Dompé US, Inc, EyePoint Pharmaceuticals*, Glaukos Corporation, Glint Pharmaceuticals, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, Inc, Leo Pharma, Novaliq GmbH, Novartis Pharmaceuticals Corporation, Ocular Science, Ocular Therapeutix, Inc, Shenyang Sinqi Pharmaceutical Co, Ltd, Sun Pharmaceutical Industries, Inc, TearLab Corporation, Thea Pharmaceuticals Limited, Verséa Health, Inc, Visus Therapeutics, Yuyu Pharma, Inc, and Zeiss; is a contracted researcher for Aerie Pharmaceuticals, Inc*, and Glaukos Corporation; and has stocks or stock options in RxSIGHT.

Jaclyn Garlich, OD, is a consultant for Lumenis, Ophthalmic Resources Partners, Orasis Pharmaceuticals, Tarsus Pharmaceuticals, Inc, and Thea Pharmaceuticals Limited; is an advisory board member of Aldeyra Therapeutics, Bruder Healthcare, and Novartis Pharmaceuticals Corporation; and is on the speakers bureau for Allergan.

* The financial relationship existed during the last 24 months but has now ended

Peer Reviewer

This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.

Planners, Managers, and Writers

MedEdicus and Amedco planners, managers, and writers have no relevant commercial relationships to disclose.

Accreditation Statement

MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

MedEdicus LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

COPE approved for 0.5 CE credit for optometrists.
COPE Course ID: 88928-TD (Asynchronous)
COPE Course Category: Treatment/Management of Ocular Disease


This activity, COPE Activity Number 127483, is accredited by COPE for continuing education for optometrists.

Disclosure of Commercial Support

MedEdicus has received commercial support from Bausch & Lomb Incorporated for this activity in the form of an unrestricted educational grant.

The content of this ACCME-/COPE-accredited CME/CE activity was planned and prepared independently by MedEdicus without input from members of an ineligible company.

Off-Label Discussion

This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.

Sponsored by

Provider Contact Information

For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.


The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC, State University of New York College of Optometry, or Bausch & Lomb Incorporated.

©2024 MedEdicus LLC. 302.1B

Available Credit

  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 COPE
  • 0.50 Participation
Please login or register to take this course.

Clicking Register/Take course indicates that you have reviewed the CME/CE information for this activity.